Trial Profile

A whole body application of QRX003 to a second pediatric Netherton patient

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QRX 003 (Primary)
Indications Netherton Syndrome
Focus Adverse reactions

Most Recent Events

07 May 2026 According to Quoin Pharmaceuticals media release, the company will submit clinical data from the pediatric trials and plans to request a meeting to discuss this data with the FDA prior to initiating the Phase 3 pivotal program to gain alignment on the design of the program.
07 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com